Avoro Capital Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Avoro Capital Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163M	Buy	23,888,888 +2,188,888	+10%	+$13M	1.46%	16
2026 Q1	$97M	Hold	21,700,000	–	–	0.95%	20
2025 Q4	$119M	Hold	21,700,000	–	–	1.17%	21
2025 Q3	$71M	Hold	21,700,000	–	–	0.92%	22
2025 Q2	$50.1M	Buy	21,700,000 +1,700,001	+9%	+$3.69M	0.88%	22
2025 Q1	$27.8M	Hold	19,999,999	–	–	0.43%	28
2024 Q4	$34.6M	Buy	19,999,999 +1,349,999	+7%	+$2.8M	0.49%	28
2024 Q3	$37.5M	Hold	18,650,000	–	–	0.55%	29
2024 Q2	$41.8M	Hold	18,650,000	–	–	0.56%	31
2024 Q1	$53.5M	Buy	18,650,000 +14,294,445	+328%	+$29.8M	0.62%	30
2023 Q4	$7.71M	Buy	4,355,555 +430,555	+11%	+$858K	0.11%	41
2023 Q3	$12.4M	Buy	+3,925,000	New	+$7.33M	0.19%	37

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Avoro Capital Advisors's TSHA Position: Q2 2026 in Review

Avoro Capital Advisors increased its Taysha Gene Therapies (TSHA) stake by 10% in Q2 2026, buying an estimated $13M and bringing the position to 23,888,888 shares worth $163M. The position accounts for 1.46% of the portfolio, ranked #16.

Avoro Capital Advisors first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Avoro Capital Advisors held 23,888,888 shares of Taysha Gene Therapies worth $163M as of Q2 2026.
Avoro Capital Advisors bought 2,188,888 Taysha Gene Therapies shares in Q2 2026, an estimated $13M.
Taysha Gene Therapies made up 1.46% of Avoro Capital Advisors's portfolio in Q2 2026, its #16 holding.
Avoro Capital Advisors first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.